Aaron Khaimraj

Aaron Khaimraj

Auto-generated profile, based on publicly available information

Aaron Khaimraj

Department of Pharmacology, University of Minnesota , Minneapolis, MN

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2022 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
DHDustin Hicks
Dustin Hicks
CBCarly Baehr
Carly Baehr
PSPedro Silva-Ortiz
Pedro Silva-Ortiz
AKAaron Khaimraj
Aaron Khaimraj
DLDiego Luengas
Diego Luengas
MPMarco Pravetoni
Marco Pravetoni
Innovative therapies to complement current treatments are needed to curb the growing incidence of fatal overdoses related to synthetic opioids. Murine and chimeric monoclonal antibodies (mAb) specific for fentanyl and its analogs have demonstrated pre-clinical efficacy in preventing and reversing drug-induced toxicity in rodent models. However, mAb-based therapeutics require extensive engineering as well as in vitro and in vivo characterization to advance to first-in-human clinical trials. Here, novel murine anti-fentanyl mAbs were selected for development based on affinity for fentanyl, and efficacy in counteracting the pharmacological effects of fentanyl in mice. Humanization and evaluation of mutations designed to eliminate predicted post-translational modifications resulted in two humanized mAbs that were effective at preventing fentanyl-induced pharmacological effects in rats. These humanized mAbs showed favorable biophysical properties with respect to aggregation and hydrophobicity by chromatography-based assays, and thermostability by dynamic scanning fluorimetry. These results collectively support that the humanized anti-fentanyl mAbs developed herein warrant further clinical development for treatment of fentanyl toxicity.

17 July 2024 in The Journal of Immunology
Verified
Journal Article
Closed access
AKAaron Khaimraj
Aaron Khaimraj
CBCarly Baehr
Carly Baehr
DHDustin Hicks
Dustin Hicks
MRMichael D Raleigh
Michael D Raleigh
MPMarco Pravetoni
Marco Pravetoni
Fentanyl and other synthetic opioids are the leading cause of drug-related deaths in the United States. mAbs that selectively target fentanyl and fentanyl analogues offer a promising strategy for treating both opioid-related overdoses and opioid use disorders. To increase the duration of efficacy of a candidate mAb against fentanyl, we selected three sets of mutations in the Fc region of an IgG1 anti-fentanyl mAb (HY6-F9DF215, HY6-F9DHS, HY6-F9YTE) to increase binding to the neonatal Fc receptor (FcRn). The mAb mutants were compared against unmodified (wild-type [WT], HY6-F9WT) anti-fentanyl mAb for fentanyl binding, thermal stability, and FcRn affinity in vitro, and for efficacy against fentanyl and mAb half-life in vivo in mice. Biolayer interferometry showed a >10-fold increase in the affinity for recombinant FcRn of the three mutant mAbs compared with HY6-F9WT. During an acute fentanyl challenge in mice, all FcRn-mutated mAbs provided equal protection against fentanyl-induced effects, and all mAbs reduced brain fentanyl levels compared with the saline group. Serum persistence of the mutant mAbs was tested in Tg276 transgenic mice expressing human FcRn. After administration of 40 mg/kg HY6-F9WT, HY6-F9DF215, HY6-F9DHS, and HY6-F9YTE, the mAbs showed half-lives of 6.3, 26.4, 14.7, and 6.9 d, respectively. These data suggest that modification of mAbs against fentanyl to bind to FcRn with higher affinity can increase their half-life relative to WT mAbs while maintaining efficacy against the toxic effects of fentanyl, further supporting their potential role as a therapeutic treatment option for opioid use disorder and overdose.

23 March 2023 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
CBCarly Baehr
Carly Baehr
AKAndrew J. Kassick
Andrew J. Kassick
JVJennifer Vigliaturo
Jennifer Vigliaturo
DLDiego Luengas
Diego Luengas
AKAaron Khaimraj
Aaron Khaimraj
MRMichael D. Raleigh
Michael D. Raleigh

11 October 2024 in The Journal of Immunology
Verified
Journal Article
Closed access
JDJenna K Dick
Jenna K Dick
JSJules A Sangala
Jules A Sangala
VKVenkatramana Divana Krishna
Venkatramana Divana Krishna
AKAaron Khaimraj
Aaron Khaimraj
LHLydia Hamel
Lydia Hamel
GHGeoffrey T Hart
Geoffrey T Hart
Multisystem inflammatory syndrome in children (MIS-C) is a severe complication of SARS-CoV-2 infection characterized by multiorgan involvement and inflammation. Testing of cellular function ex vivo to understand the aberrant immune response in MIS-C is limited. Despite strong Ab production in MIS-C, SARS-CoV-2 nucleic acid testing can remain positive for 4–6 wk postinfection. Therefore, we hypothesized that dysfunctional cell-mediated Ab responses downstream of Ab production may be responsible for delayed clearance of viral products in MIS-C. In MIS-C, monocytes were hyperfunctional for phagocytosis and cytokine production, whereas NK cells were hypofunctional for both killing and cytokine production. The decreased NK cell cytotoxicity correlated with an NK exhaustion marker signature and systemic IL-6 levels. Potentially providing a therapeutic option, cellular engagers of CD16 and SARS-CoV-2 proteins were found to rescue NK cell function in vitro. Taken together, our results reveal dysregulation in Ab-mediated cellular responses of myeloid and NK cells that likely contribute to the immune pathology of this disease.

18 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
JDJenna K Dick
Jenna K Dick
JSJules A Sangala
Jules A Sangala
VKVenkatramana Divana Krishna
Venkatramana Divana Krishna
AKAaron Khaimraj
Aaron Khaimraj
LHLydia Hamel
Lydia Hamel
GHGeoffrey T Hart
Geoffrey T Hart
Multisystem Inflammatory Syndrome in Children (MIS-C) is a severe complication of SARS-CoV-2 infection characterized by multi-organ involvement and inflammation. Testing of cellular function ex vivo to understand the aberrant immune response in MIS-C is limited. Despite strong antibody production in MIS-C, SARS-CoV-2 nucleic acid testing can remain positive for 4-6 weeks after infection. Therefore, we hypothesized that dysfunctional cell-mediated antibody responses downstream of antibody production may be responsible for delayed clearance of viral products in MIS-C. In MIS-C, monocytes were hyperfunctional for phagocytosis and cytokine production, while natural killer (NK) cells were hypofunctional for both killing and cytokine production. The decreased NK cell cytotoxicity correlated with an NK exhaustion marker signature and systemic IL-6 levels. Potentially providing a therapeutic option, cellular engagers of CD16 and SARS-CoV-2 proteins were found to rescue NK cell function in vitro. Together, our results reveal dysregulation in antibody-mediated cellular responses unique to MIS-C that likely contribute to the immune pathology of this disease. Summary MIS-C is a severe complication of SARS-CoV-2 infection characterized by multi-organ involvement and inflammation. Limited studies tested cellular function ex vivo to understand the aberrant immune response in MIS-C. We found dysregulation in antibody-mediated cellular responses unique to MIS-C that likely contribute to the immune pathology of this disease

17 March 2025 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
CBCarly Baehr
Carly Baehr
RJRajwana Jahan
Rajwana Jahan
AGAnn Gebo
Ann Gebo
JVJennifer Vigliaturo
Jennifer Vigliaturo
DSDaihyun Song
Daihyun Song
MPMarco Pravetoni
Marco Pravetoni